Home' Australian Pharmacist : October 2011 Contents Vol. 30 -- October #10, 2011
Continuing Professional Development
Submit your answers online at www.psa.org.au and receive automatic feedback
Note: The CPD questions are now at
the end of each article.
PSA members can answer online at
www.psa.org.au and receive automatic feedback.
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from the
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
Submit your answers before 1 December 2011
or fax/mail to:
(04) 381 4786
NZCP Mail address: NZCP CPD answers
PO Box 11 640
(03) 9389 4044
PSA Mail address: PSA CPD answers
PSA Victorian Branch
Level 1, 381 Royal Parade
PARKVILLE VIC 3052
online at www.psa.org.au and receive automatic feedback
Australian Pharmacist Continuing Professional Development (CPD) is a central
element of PSA's CPD&PI program. It is also part of the New Zealand College of
Pharmacists (NZCP) education program for NZ pharmacists.
The CPD section is recognised under the PSA CPD&PI program as a Group 2 activity.
Members can choose which articles they want to answer questions on and get CPD
credits based on the questions they answer. The credits allocated to each section
and the pass mark are shown with the questions.
CPD credits are allocated as follows: a minimum of 6 out of 8 questions correct
attracts 1.5 credits, a minimum of 4 out of 5 questions correct attracts 1 credit, and
a minimum of 3 out of 4 questions correct attracts three quarters of a credit.
If not submitting online, write the correct answers in the spaces provided on the
answer panel on the back of the address sheet, fill in your name, member number
and address details, then either mail or fax the answer page to the relevant address
and fax number for marking.
the same? A comparative review of data pertaining to
pharmacological and physiological. aspects. Eur J Ger.
2007; 9(Suppl. 1):29--42.
11. Therapeutic Guidelines. Drugs used for the treatment
of bladder symptoms in neurological disorders [CD].
Melbourne: Therapeutic Guidelines; 2011.
12. Franks M, Chartier-Kastler E, Chancellor MB. New
pharmacologic and minimally invasive therapies for the
overactive bladder. Medscape [online] 2000 [accessed
Jul 2011]. At: www.medscape.com/viewarticle/409922
13. Australian Medicines Handbook. Anticholinergics.
Adelaide: AMH; 2011.
14. Australian Medicines Handbook. Tolterodine. Adelaide:
15. Australian Medicines Handbook. Solifenacin. Adelaide:
16. Australian Medicines Handbook. Darifenacin. Adelaide:
17. Zinner N, Tuttle J, Marks L. Efficacy and tolerability
of darifenacin, a muscarinic M3 selective receptor
antagonist (M3 SRA), compared with oxybutynin in the
treatment of patients with overactive bladder. World J
Urol. 2005; 23:248--52.
18. Kuteesa W, Moore KH. Anticholinergic drugs for
overactive bladder. Aust Prescr. 2006; 29:22--4.
19. Australian Medicines Handbook. Imipramine. Adelaide:
20. eMIMS. Prescribing Information: Digibind Monograph.
St Leonards, NSW: MediMedia; 2011.
21. Australian Medicines Handbook. Prazosin. Adelaide:
1. Which of the following are
ALL risk factors for overactive
a) Parkinson's disease, asthma, high
b) High alcohol intake, stroke,
c) Obesity, diabetes, oestrogen
d) Heart failure, younger age,
2. Which of the following is
NOT a symptom of overactive
d) Pain on micturition.
3. Which of the following is the
BEST option for someone
who has found behavioural
strategies in the treatment of
overactive bladder syndrome
only of partial benefit?
a) Wear an incontinence pad.
b) Cease behavioural treatment and
commence oxybutynin 2.5 mg
three times daily.
c) Commence oxybutynin 2.5 mg
three times daily and continue with
d) Restrict water intake.
4. Which of the following are ALL
adverse effects associated with
the use of the anticholinergic
agents used in the treatment of
overactive bladder syndrome?
A score of 4 out of 5 attracts 1 CPD credit.
a) Dry mouth, blurred vision, fatigue.
b) Constipation, ankle oedema, hair
c) Sweating, double vision,
d) Dry mouth, diarrhoea, blurred
5. Solifenacin is a bladder-
selective muscarinic agent
and is therefore less likely
than oxybutynin to cause dry
b) True, only when solifenacin is
taken at the 5 mg initiation dose.
Links Archive November 2011 September 2011 Navigation Previous Page Next Page